Our Science

Building on results obtained in our initial development program targeting Parkinson's Disease (PD), we could already provide preclinical proof-of-concept for WISIT vaccines targeting human aSynuclein and demonstrated that these neoglucoconjugates are superior to conventional type PD conjugate vaccines in eliciting functional, protective antibody responses in vitro and in vivo (Schmidhuber et al 2022).